linjc16/ctgov huggingface dataset:
Endoscopic Stomach and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
The Roux-En-Y gastric bypass procedure is the most commonly performed bariatric procedure in the United States. Despite initial weight loss, some patients experience weight regain that may be related to an increase in the size of the gastric pouch and/or stoma. A second surgical procedure to reduce the size of the pouch and/or stoma is typically associated with a higher risk of death or complications than the original gastric bypass procedure. This study will evaluate a less invasive, endolumenal alternative to pouch and stoma revision as a means of producing weight loss in patients who have regained weight following gastric bypass.

Official Title
-----------------
Use of a New Endosurgical Operating System for Endoscopic Stoma and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Procedure: endolumenal surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 yrs of age or older and < 65 yrs of age At least 2 yrs post-Roux-En-Y gastric bypass surgery Initially achieved at least 50% weight loss At enrollment, has regain at least 15% of weight loss BMI 40 or greater or 35 or greater with one or more co-morbidities Stoma diameter at least 20 mm Completes successful nutritional screening Is a candidate for a surgical revision procedure Is a reasonable risk to undergo general anesthesia Completes successful cardiopulmonary evaluation ASA Classification of less than or equal to III Able to provide written consent Able to return for protocol-specified evaluations Exclusion Criteria: Esophageal stricture or other anatomy/condition that precludes passage of endolumenal instruments Previous bariatric revision procedure Has another causal factor for weight regain other than stoma or pouch dilatation Non-mobile or has significant impairment of mobility that will limit compliance with post-op exercise program

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: endolumenal surgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss |  |  |
Epidemiological Landscape of Cervical Cancer in Latin America

Study Overview
=================
Brief Summary
-----------------
A portrait of clinical and epidemiological aspects of cervical cancer in Latin America is required to understand the high frequency of cervical cancer despite the existence of effective preventive tools. A better understanding of the current situation of this scenario will provide a valuable groundwork for the development of national and cooperative programs to improve cervical cancer prevention and treatment.

Official Title
-----------------
Epidemiological Landscape of Cervical Cancer in Latin America .

Conditions
-----------------
Uterine Cervical Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women > 18 years. Histologically proven cervical carcinoma Diagnosis of carcinoma of the cervix since January 2018 or newly diagnosis or recurrent disease during the period of study recruitment. Any histology of cervical cancer at time of diagnosis. FIGO stage IB2-IVA Have available and adequate medical records for data collection Accept to participate in the project and sign the informed consent (if applicable) Exclusion Criteria: FIGO stage I and IB1 Non-invasive cervical cancer Synchronous tumor or second primary tumor in the last five years (exception for thyroid cancer or skin cancer non melanoma)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| - Summarize the histologic subtype | Summarize the histologic subtype, assessed by the anatomopathological assay of the tumor sample and the stage at diagnosis, assessed by FIGO stage (International Federation of Gynecology and Obstetrics (FIGO) staging of cancer of the cervix uteri - 2018), using gynecological exam. Image studies and TNM stage (AJCC 8th edition) will also be used to assess stage at diagnosis when available. | January of 2028 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical Neoplasms
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)

Study Overview
=================
Brief Summary
-----------------
The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin

Detailed Description
-----------------
The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin. SFI analyzes the topical staining of the skin surface using the ORL-1 dye to reveal the presence of remodeling in the skin, together with the visible feature characteristics. The system provides a biometric score corresponding to the dye staining, a structural score, and a composite SFI score to quantify the presence of tissue remodeling and the process of melanocytic transition in the skin.

Official Title
-----------------
Assessing Tissue Remodeling in the Skin Using Skin Fluorescence Imaging (SFI)

Conditions
-----------------
Skin Lesion, Melanoma (Skin), Mole

Intervention / Treatment
-----------------
* Other: Diagnostic Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with a pigmented skin lesion recommended for a skin biopsy. A lesion that is accessible to the imaging device, with at least 1 cm of skin around the lesion that is accessible to the MDS. At least 21 years old. Written, signed, and dated informed consent Scheduled for a primary excision/biopsy as part of the clinics SOC. Exclusion Criteria: Lesion is less than 1 centimeter from the eyes. Lesion is on the palms of the hands or soles of the feet. Mucosal lesion. Ulcerated lesion. Subject is pregnant or planning to become pregnant during the study period. Patients who are mentally or physically unable to comply with all aspects of the study. Any subject undergoing chemotherapy. Any lesion that has been treated with local anesthesia such as lidocaine prior to enrollment that would confound study results.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Suspicious Nevi undergoing biopsy<br>Subject with suspicious Nevi undergoing biopsy per SOC | Other: Diagnostic Test<br>* Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy<br>* Other names: SFI 001 Imaging;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation | To identify histological features that correlate with the imaging features captured using SFI | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nevus, Melanoma, Mole, Atypical Nevi
Comparing Oxygen Saturation in Post Anesthesia Care Unit After Different Methods of Pain Relief

Study Overview
=================
Brief Summary
-----------------
To determine the which method of pain relief is better after current anesthesia care.

Detailed Description
-----------------
We hypothesized that in children, the current anesthesia care (combined light general anesthesia and caudal analgesia) may decrease incidence of intra and or postoperative de-saturation( SaO2 < %95), the need of oxygen during child's transport to the PACU and during his stay in the recovery room, compared with children who receive intravenous narcotics for intra and postoperative pain relief.

Official Title
-----------------
Oxygen Saturation During Transfer From Operating Room to Post Anesthesia Care Unit After Current Anesthesia Care

Conditions
-----------------
Cryptorchidism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children ASA physical status 1 or 2 1-6 yr old Scheduled for elective uni or bilateral orchidopexy Exclusion Criteria: Children with compromised pulmonary, cardiac, neurological, hematological, renal condition, with history of prematurely or are obese will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational<br>Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Caudal Block, Oxygen Saturation, Uni or Bilateral Orchidopexy
INSTrUCT-SCI: INdependent Observational STUdy of Cell Transplantation in SCI

Study Overview
=================
Brief Summary
-----------------
The investigation is a multi-year observational study following the completion of the open-label, single dose Phase I/II study involving transplantation of allogeneic HuCNS-SC cells into 12 subjects with thoracic spinal cord injury. Subjects will be monitored at routine intervals for safety and preliminary efficacy for 5 years post-transplantation of the Phase I/II investigation CL-N02-SC.

Official Title
-----------------
INSTrUCT-SCI: INdependent Observational STUdy of Cell Transplantation in SCI, an Investigator Initiated Trial

Conditions
-----------------
Spinal Cord Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have undergone HuCNS-SC transplantation as a subject in the Phase I/II trial Must be able to provide written informed consent prior to any study related procedures Must agree to comply in good faith with all conditions of the study and to attend all required study visits Female subjects who are pregnant remain eligible for enrollment, but the MRI examination will not be performed during the pregnancy. Female subjects of child-bearing potential must have a negative urine pregnancy test prior to the MRI examination Exclusion Criteria: Subjects have received or are receiving off-protocol immunosuppressive medications Subjects who after completion of CL-N02-SC have entered, or are about to enter any other interventional study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| American Spinal Injury Association (ASIA) Impairment Scale Improvement | Evidence of improvement in ASIA impairment scale as confirmed by neurological examination | 36 months after transplantation of HuCNS-SC® |
Relationship Between Computer and Cancer

Study Overview
=================
Brief Summary
-----------------
Thyroid Cancer is one of the most common malignant carcinomas. The incidence of thyroid cancer has risen in the past years. The recrudesce rate is highly raised. Computer is widely used by people nowadays, is it a predisposing factor to the highly raised recrudesce rate? This research observed two random assigned groups, in which the patients were diagnosed by pathologic results. One group were strictly prohibit with using computer, the other were not told. Finally collect the recrudesce rate of each group, analyze the data by statistic software.

Official Title
-----------------
Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer

Conditions
-----------------
Thyroid Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thyroid cancer Exclusion Criteria: Non-Thyroid cancer

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Compuer radiaton group<br> | |
| control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Level of Burn Out of Surgical Residents Working in All Hospitals of Lahore

Study Overview
=================
Brief Summary
-----------------
The term burnout was coined by psychologist Herbert Freudenberger in 1974 in an article entitled Staff Burnout in which he discussed job dissatisfaction precipitated by work-related stress. A broadly applicable description defines burnout as a state of mental and physical exhaustion related to work or care giving activities. A long-standing conceptual and operational definition characterized burnout as a triad of emotional exhaustion (emotional over extension and exhaustion), depersonalization (negative, callous, and detached responses to others), and reduced personal accomplishment (feelings of competence and achievement in one's work) In the World Health Organization International Classification of Diseases, 10th revision, burnout is defined as a state of vital exhaustion. Although no specific diagnosis of burnout is mentioned in the Diagnostic and Statistical Manual of Mental Disorders, burnout is a clear syndrome with significant consequences. Burnout in health care professionals has gained significant attention over the last several years. Given the intense emotional demands of the work environment, clinicians are particularly susceptible to developing burnout above and beyond usual workplace stress. Residency training, in particular, can cause a significant degree of burnout, leading to interference with individuals' ability to establish rapport, sort through diagnostic dilemmas, and work though complex treatment decision making. Overall, burnout is associated with a variety of negative consequences including depression, risk of medical errors, and negative effects on patient safety. The goal of this review is to provide medical educators and leaders with an overview of the existing factors that contribute to burnout, the impact of burnout, inter specialty variation, and suggestions for interventions to decrease burnout.

Official Title
-----------------
Burn Out Among Surgical Residents Working at All Institutes in Lahore: An Area of Grave Concerns

Conditions
-----------------
Burn Out Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: General Surgical resident Exclusion Criteria: Residents of all other specialties All the General surgical consultants

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| average working hours of residents | working hours of the residents will be noted and will be used this information to evaluate whether increased work hours lead to emotional instability and emotional exhaustion among them or not. | upto 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| emotional exhaustion |  | 3 months |
TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

Study Overview
=================
Brief Summary
-----------------
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).

Official Title
-----------------
Turbo Power Laser Atherectomy Combined With Drug Coated Balloon Angioplasty for the Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Device: Laser Atherectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients treated for femoropopliteal de novo/restenotic lesions or in-stent restenosis using Turbo Power laser atherectomy plus drug coated balloon angioplasty Exclusion Criteria: Any incomplete data on procedural approach and treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants Free From Target Lesion Revascularization (TLR) | A Target Lesion Revascularization is defined as any percutaneous or surgical intervention to treat a restenosis or reocclusion in the target lesion | 1 year |
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Study Overview
=================
Brief Summary
-----------------
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4 cycles of non-cisplatin moderately emetogenic chemotherapy.

Official Title
-----------------
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy

Conditions
-----------------
Nausea, Vomiting, Breast Neoplasms

Intervention / Treatment
-----------------
* Drug: MK0869, aprepitant / Duration of Treatment: 3 days
* Drug: Comparator: ondansetron / Duration of Treatment: 3 days


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy. Exclusion Criteria: Patient has a central nervous system malignancy. Patient will receive radiation to the abdomen or pelvis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0869, aprepitant / Duration of Treatment: 3 days|nan|
|Drug: Comparator: ondansetron / Duration of Treatment: 3 days|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emesis and use of rescue medication |  |  | 
| Safety and tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chemotherapy-Induced Nausea and Vomiting
Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Observational Study of Pain Reduction in Late Stage Cancer Patients Receiving Low-Dose Chemotherapy

Detailed Description
-----------------
Observational Study of Pain Reduction in Late Stage Cancer Patients who are Receiving Low-Dose Chemotherapy (Metabolic Targeting)

Official Title
-----------------
Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy

Conditions
-----------------
Acute Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient requests to be included in this study Exclusion Criteria: Patient does not request to be included in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Level Self Assessment | From enrollment in study to termination of study (August 2020) | 5 years |